Randomized, controlled, double-blinded clinical trial of oral Cry j1-galactomannan conjugate immunotherapy for Japanese cedar pollen allergy - RCT of Cry j1-galactomannan conjugate OIT for Japanese cedar pollen allergy

Mean symptom-medication score as the primary outcome in the active group improved 27.8% relative to the placebo group during the entire pollen season. As the secondary outcomes, mean medication score in active group improved significantly, by 56.2%, compared with placebo during the entire pollen season. Mean total symptom score was similar between active and placebo groups during the entire pollen season. There were no severe treatment-emergent adverse events in the active and placebo groups.